| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $158,727,866 ) (Continued on the next page) |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA272390 | DF/HCC Prostate SPORE | 000 | 1 | NIH | 8/30/2023 | $2,585,567 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA271492 | Molecular prediction of myeloma in African Americans | 000 | 2 | NIH | 8/24/2023 | $855,498 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 1 | NIH | 11/30/2022 | $129,001 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA273043 | Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention | 000 | 2 | NIH | 6/23/2023 | $254,492 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA261863 | STEP-YA: An Online Self-Management Intervention for Young Adult Cancer Survivors with Insomnia | 001 | 2 | NIH | 9/13/2023 | $4,094 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00DK123321 | Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders | 000 | 4 | NIH | 2/16/2023 | $249,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA259273 | Defining epigenetic mechanisms in NPM1c mutant leukemia | 000 | 3 | NIH | 3/22/2023 | $395,535 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 001 | 10 | NIH | 4/11/2023 | $300,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 000 | 10 | NIH | 2/28/2023 | $7,266,451 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 004 | 58 | NIH | 9/15/2023 | $100,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R37AI039394 | Biochemical Mechanism of HIV DNA Integration | 000 | 28 | NIH | 5/19/2023 | $679,163 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 003 | 58 | NIH | 7/24/2023 | $224,723 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 005 | 58 | NIH | 9/18/2023 | $495,880 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 000 | 11 | NIH | 7/27/2023 | $2,498,796 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 006 | 58 | NIH | 9/22/2023 | $224,723 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 006 | 58 | NIH | 9/22/2023 | -$224,723 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 12 | NIH | 4/12/2023 | $751,633 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 002 | 58 | NIH | 6/23/2023 | $208,750 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 000 | 58 | NIH | 1/25/2023 | $12,713,161 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P30CA006516 | Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer | 001 | 58 | NIH | 6/15/2023 | $0 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA127003 | Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer | 002 | 15 | NIH | 6/30/2023 | $2,248,301 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK082889 | Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | 001 | 11 | NIH | 2/22/2023 | $372,621 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U54CA156732 | Advancing research methods to better understand health literacy and health equity in digital communications | 002 | 13 | NIH | 9/6/2023 | $103,666 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U54CA156732 | Advancing research methods to better understand health literacy and health equity in digital communications | 001 | 13 | NIH | 8/29/2023 | $1,730,738 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA100707 | SPORE in Multiple Myeloma | 001 | 20 | NIH | 7/6/2023 | $2,257,199 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | T32CA136432 | Research Training in Pediatric Oncology | 000 | 14 | NIH | 6/28/2023 | $445,947 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA168504 | Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer | 001 | 10 | NIH | 7/21/2023 | $2,302,230 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 001 | 24 | NIH | 9/18/2023 | $39,332 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 000 | 24 | NIH | 5/3/2023 | $1,927,163 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 000 | 11 | NIH | 2/22/2023 | $507,874 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UH3CA240688 | Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors | 001 | 4 | NIH | 5/5/2023 | $362,332 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA270069 | Development of A Mindfulness-Based Mobile Health Intervention for Patients Coping with Pain from Advanced Malignancies | 000 | 2 | NIH | 4/6/2023 | $204,494 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K99CA267082 | Modeling and Dissecting Epigenetic Drivers of Gliomagenesis | 000 | 2 | NIH | 2/28/2023 | $167,400 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA248393 | Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | 000 | 3 | NIH | 3/24/2023 | $539,860 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32CA254118 | Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling | 001 | 3 | NIH | 5/22/2023 | $2,038 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U01HG010961 | The construction and utility of reference pan-genome graphs | 002 | 3 | NIH | 6/26/2023 | $801,988 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R35CA242427 | Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | 000 | 5 | NIH | 6/19/2023 | $1,016,184 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK117655 | Small molecules targeting hepatic glucose production and insulin resistance | 000 | 5 | NIH | 2/28/2023 | $650,222 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA239660 | The Function of CDK5 in Metastasis | 000 | 5 | NIH | 2/27/2023 | $432,500 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA201049 | Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M | 001 | 8 | NIH | 3/16/2023 | $39,242 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA201049 | Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M | 000 | 8 | NIH | 12/16/2022 | $441,496 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32CA281185 | Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes | 000 | 1 | NIH | 5/11/2023 | $69,080 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 000 | 1 | NIH | 1/27/2023 | $741,387 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 000 | 1 | NIH | 1/12/2023 | $67,174 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA272982 | Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers | 001 | 2 | NIH | 9/1/2023 | $389,092 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267527 | Defining the impact of mutational drivers on the immune microenvironment of CLL | 001 | 2 | NIH | 1/27/2023 | $203,878 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK132544 | Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes | 000 | 2 | NIH | 3/20/2023 | $445,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA262710 | Statistical methods for cancer mutational signatures | 000 | 3 | NIH | 8/23/2023 | $231,105 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08DK130790 | Insights from somatic genomics lead to novel therapeutic targets in inherited bone marrow failure syndromes: Shwachman-Diamond Syndrome as a model. | 000 | 3 | NIH | 3/10/2023 | $134,881 |
|
